Enterome vs iDEL Therapeutics
Enterome vs iDEL Therapeutics, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Enterome is on 60/100 and iDEL Therapeutics on 45/100.
Where each one leads
Enterome
- our overall score: 60/100 against 45/100
- domain rating: 46/100 against 10/100
- funding raised: $124M against $9.7M
iDEL Therapeutics
- agent readiness: 32/100 against 21/100
At a glance
| Measure | Enterome | iDEL Therapeutics |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. | Developing a pipeline of cancer therapeutics delivered directly into the cytosol of tumor cells. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biotechnology, Pharmaceuticals, Oncology, Drug Delivery |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 2012 | 2025 |
| Headquarters | Paris, France | Dortmund, Germany |
| Status | Active | Active |
Size, funding and growth
| Measure | Enterome | iDEL Therapeutics |
|---|---|---|
| Employees | 33 | Not published |
| Total funding | $124M | $9.7M |
| Latest round | Later Stage VC | Seed |
| LinkedIn followers | 16,846 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Enterome | iDEL Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 45/100 |
| Traction | 55/100 | 35/100 |
| Team | 70/100 | 30/100 |
| Community | Not published | 15/100 |
| Search visibility | 34/100 | 14/100 |
| Quality | 68/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (32/100) |
| Domain ratingLink authority, 0-100 | 46/100 | 10/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Enterome | iDEL Therapeutics |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | WordPress | WordPress |
| Frameworks | Bootstrap | Jquery, Bootstrap |
| Analytics | Google Analytics 4, Segment | Google Analytics 4 |
Enterome vs iDEL Therapeutics: common questions
Which is better, Enterome or iDEL Therapeutics?
On our 0-100 score Enterome rates higher (60/100 against 45/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Enterome and iDEL Therapeutics compare on the numbers?
Enterome leads on our overall score (60/100 against 45/100), domain rating (46/100 against 10/100), funding raised ($124M against $9.7M). iDEL Therapeutics leads on agent readiness (32/100 against 21/100).
Read the full Enterome review and pricing or the iDEL Therapeutics review and pricing. You can also browse other Enterome alternatives we track.